摘要
目的探讨老年2型糖尿病患者口服吡格列酮对发生急性心肌梗死时血清基质金属蛋白酶9和C反应蛋白浓度的影响。方法选择合并2型糖尿病的老年急性心肌梗死患者37例,按发病前有无口服吡格列酮分为吡格列酮组(17例)和急性心肌梗死组(20例),另选择老年健康体检者23例作为对照组,抽血测定三组血清基质金属蛋白酶9和C反应蛋白的浓度,并进行比较。结果与对照组相比,急性心肌梗死组血清基质金属蛋白酶9(396.5±67.3μg/L比290.8±75.5μg/L)和C反应蛋白浓度(8.73±2.59 mg/L比3.21±1.11 mg/L)明显升高,吡格列酮可降低血清基质金属蛋白酶9浓度(339.2±79.8μg/L)和C反应蛋白浓度(6.33±2.25 mg/L)。结论吡格列酮可降低老年急性心肌梗死患者血清基质金属蛋白酶9和C反应蛋白水平,提示吡格列酮在改善胰岛素敏感性之外还对心血管系统有益。
Ahn To investigate the effects of pioglitazone on serum matrix metalloproteinase-9 （MMP-9） and C-reactive protein （CRP） concentration in the elderly patients with acute myocardial infarction （AMI） and type-2 diabetic mellitus. Methods 37 cases of AMI patients accompanied with type-2 diabetic mellitus were divided into two groups according to the administration of pioglitazone previously： pioglitazonegroup（17cases） andAMIgroup（20cases）. 23 aged people of heahh physical examination were enrolled as health control group. The concentrations of serum MMP-9 and CRP were measured in all of the patients. Results The concentration of serum MMP-9 and CRP in AMI group were higher than ~ in health control group （396.5±67μg/Lvs290.8±75.5μg/L, 8.73±2.59mg/L vs3.21±1.11mg/L）. TheconcentrafionofsenunMMP-9 （339.2±79.8 μg/L） and CRP （6.33±2.25 μg/L） in pioglitazone group were lower than those in AMI group. Conclusion Pioglitazone can lower the concentration of serum MMP-9 and CRP level. Pioglitazone has additional cardiovascular effects beside the improvement of insulin resistance.
出处
《中国动脉硬化杂志》
CAS
CSCD
2007年第9期711-713,共3页
Chinese Journal of Arteriosclerosis
